Damaris Priscila Romero-Rodríguez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Damaris Priscila Romero-Rodríguez has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Torres-Flores
Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
1 shared publication - Andrés Ademar Garcia-Nuñez
Laboratorio de Inmunofarmacología, Unidad Profesional Interdisciplinaria de Biotecnología, Instituto Politécnico Nacional, Mexico City 07340, Mexico
1 shared publication - Angel Daniel Campos Juarez
Instituto Politécnico Nacional Unidad Profesional Interdisciplinaria de Biotecnología Mexico City Mexico
1 shared publication - Carlos Zepactonal Gómez Castro
Universidad Autónoma del Estado de Hidalgo
1 shared publication - Claudia Carranza
Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias (INER) “Ismael Cosío Villegas”, Mexico City 14080, Mexico
1 shared publication - Constantino López-Macías
Unidad de Investigación Médica en Inmunoquímica, UMAE Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico
1 shared publication
Latest Publications
- Open Access
- 3 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2232
Systemic T-Cell Activation Landscapes Elicited Following Intramuscular and Intranasal Immunization with the Active NDV-Vectored Anti-COVID-19 Vaccine “Patria” in Humans
COVID-19 vaccines remain essential for pandemic control, but antibody responses wane, and viral variants emerge. Affordable platforms enabling local manufacturing are important for equitable vaccine access in low- and middle-income countries (LMICs). The locally developed and manufactured NDV-vectored AVX/COVID-12 “Patria” vaccine may help address this need. We conducted an exploratory analysis of antigen-specific cellular immunity in 17 healthy SARS-CoV-2-naïve volunteers from a previously reported phase I safety and immunogenicity cohort (NCT04871737). Eight participants received intramuscular (IM) and nine received intranasal (IN) vaccination. Peripheral blood collected through 90 days was stimulated in vitro with recombinant Wuhan-Spike protein and analyzed using activation-induced marker (AIM) assays, intracellular cytokine staining, and high-dimensional flow cytometry. AIM+ CD4+ T-cell frequencies peaked around day 28 at 0.45 (1.13)% after IM and 0.18 (0.6)% after IN vaccination, while AIM+ CD8+ T-cell responses remained lower, reaching 0.09 (0.22)% and 0.03 (0.33)%, respectively, median (IQR). Cytokine-producing T-cell responses showed no consistent route-related differences. High-dimensional analysis identified multiple activation-associated phenotypes in CD3+ and CD3− compartments, across both vaccination routes, with distinct temporal dynamics. These exploratory findings show systemic Spike-responsive T-cell activation in this cohort after both routes and provide a refined characterization of vaccine-induced cellular immunity, warranting further investigation of IN administration.
- 3 October 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (10) , 2232
Open AccessSystemic T-Cell Activation Landscapes Elicited Following Intramuscular and Intranasal Immunization with the Active NDV-Vectored Anti-COVID-19 Vaccine “Patria” in Humans
COVID-19 vaccines remain essential for pandemic control, but antibody responses wane, and viral variants emerge. Affordable platforms enabling local manufacturing are important for equitable vaccine access in low- and middle-income countries (LMICs). The locally developed and manufactured NDV-vectored AVX/COVID-12 “Patria” vaccine may help address this need. We conducted an exploratory analysis of antigen-specific cellular immunity in 17 healthy SARS-CoV-2-naïve volunteers from a previously reported phase I safety and immunogenicity cohort (NCT04871737). Eight participants received intramuscular (IM) and nine received intranasal (IN) vaccination. Peripheral blood collected through 90 days was stimulated in vitro with recombinant Wuhan-Spike protein and analyzed using activation-induced marker (AIM) assays, intracellular cytokine staining, and high-dimensional flow cytometry. AIM+ CD4+ T-cell frequencies peaked around day 28 at 0.45 (1.13)% after IM and 0.18 (0.6)% after IN vaccination, while AIM+ CD8+ T-cell responses remained lower, reaching 0.09 (0.22)% and 0.03 (0.33)%, respectively, median (IQR). Cytokine-producing T-cell responses showed no consistent route-related differences. High-dimensional analysis identified multiple activation-associated phenotypes in CD3+ and CD3− compartments, across both vaccination routes, with distinct temporal dynamics. These exploratory findings show systemic Spike-responsive T-cell activation in this cohort after both routes and provide a refined characterization of vaccine-induced cellular immunity, warranting further investigation of IN administration.
- Open Access
- 22 October 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (4) , 53
Nitazoxanide Shows an Immunomodulatory Effect in Vγ9Vδ2 T Cells
The γδ T cells belong to a subgroup of T cells known as non-conventional T cells due to their limited T cell receptor (TCR) repertoire and ability to recognize non-peptide antigens. They play a crucial role in combating infections and tumors. Vγ9Vδ2 T cells are typically activated by molecules containing diphosphate groups, collectively known as phosphoantigens (pAgs), through a non-canonical mechanism which involves the intracellular domain of butyrofilin (BTN)3A1 protein. However, no FDA-approved drugs have yet been shown to activate them, and the underlying cellular mechanisms remain unknown. In this study, we combined high-throughput virtual screening of an FDA-approved drug database with in vitro cellular assays to identify potential γδ T cells activators. Our findings demonstrate that Nitazoxanide (NTZ) and Tinidazole induce moderate elicited a statistically significant increase in interferon (IFN)-γ production of Vγ9Vδ2 T cells by their probably interaction with the pAg binding site of BTN3A1. Additionally, NTZ induces expression of CD107a, but only at the highest concentrations tested and promotes the upregulation of HLA-DR in total PBMCs and CD14+ monocytes. Blocking BTN3A with a specific antibody led to a marked reduction in all NTZ-induced activations. This work identifies NTZ as a previously unrecognized activator of γδ T cells, highlighting its immunomodulatory potential beyond its known clinical uses. These findings broaden our understanding of γδ T cells pharmacology and suggest new opportunities for drug repurposing and the design of novel chemical scaffolds. Further mechanistic studies will be essential to fully define how NTZ engages the BTN3A–γδ T cells axis.
- 22 October 2025
- Published by MDPI AG in Scientia Pharmaceutica
- Vol. 93 (4) , 53
Open AccessNitazoxanide Shows an Immunomodulatory Effect in Vγ9Vδ2 T Cells
The γδ T cells belong to a subgroup of T cells known as non-conventional T cells due to their limited T cell receptor (TCR) repertoire and ability to recognize non-peptide antigens. They play a crucial role in combating infections and tumors. Vγ9Vδ2 T cells are typically activated by molecules containing diphosphate groups, collectively known as phosphoantigens (pAgs), through a non-canonical mechanism which involves the intracellular domain of butyrofilin (BTN)3A1 protein. However, no FDA-approved drugs have yet been shown to activate them, and the underlying cellular mechanisms remain unknown. In this study, we combined high-throughput virtual screening of an FDA-approved drug database with in vitro cellular assays to identify potential γδ T cells activators. Our findings demonstrate that Nitazoxanide (NTZ) and Tinidazole induce moderate elicited a statistically significant increase in interferon (IFN)-γ production of Vγ9Vδ2 T cells by their probably interaction with the pAg binding site of BTN3A1. Additionally, NTZ induces expression of CD107a, but only at the highest concentrations tested and promotes the upregulation of HLA-DR in total PBMCs and CD14+ monocytes. Blocking BTN3A with a specific antibody led to a marked reduction in all NTZ-induced activations. This work identifies NTZ as a previously unrecognized activator of γδ T cells, highlighting its immunomodulatory potential beyond its known clinical uses. These findings broaden our understanding of γδ T cells pharmacology and suggest new opportunities for drug repurposing and the design of novel chemical scaffolds. Further mechanistic studies will be essential to fully define how NTZ engages the BTN3A–γδ T cells axis.